Description

Aclerastide (DSC-127) is an angiotensin receptor agonist. Aclerastide also is a peptide analog of angiotensin II. Aclerastide can be used for the research of tissue regeneration in diabetic ulcers[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–COVID-19-immunoregulation–C42H64N12O11—-[1]Kathleen E Rodgers, et al. Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7). Plast Reconstr Surg. 2003 Mar;111(3):1195-206.|[2]Trung T Nguyen, et al. Expression of active matrix metalloproteinase-9 as a likely contributor to the clinical failure of aclerastide in treatment of diabetic foot ulcers. Eur J Pharmacol. 2018 Sep 5;834:77-83.–227803-63-6–913.03–99.85–OC(C=C1)=CC=C1C[C@H](NC([C@H](CCCC)NC([C@H](CCCNC(N)=N)NC([C@@H](N)CC(O)=O)=O)=O)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC2=CN=CN2)C(N3[C@@H](CCC3)C(O)=O)=O)=O)=O–Inflammation/Immunology–DMSO : ≥ 100 mg/mL–Angiotensin Receptor—-GPCR/G Protein–Peptides